Figure 2. Associations of immune and stromal scores with clinical characteristics and prognosis in NSCLC subtypes. The LUAD and LUSC cases were respectively divided into groups with high or low median immune or stromal scores. The results represent their correlation with clinical characteristics in LUAD (A–L) and LUSC (M–X), respectively, and their correlation with overall survival in LUAD and LUSC (Y). P < 0.05 was used to assess differences in Log-rank test. NSCLC, non-small-cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.